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Summary
Background The Global Burden of Disease (GBD) study assesses health losses from diseases, injuries, and risk factors 
using disability-adjusted life-years, which need a set of disability weights to quantify health levels associated with non-
fatal outcomes. The objective of this study was to estimate disability weights for the GBD 2013 study.
Methods We analysed data from new web-based surveys of participants aged 18–65 years, completed in four European 
countries (Hungary, Italy, the Netherlands, and Sweden) between Sept 23, 2013, and Nov 11, 2013, combined with data 
previously collected in the GBD 2010 disability weights measurement study. Surveys used paired comparison 
questions for which respondents considered two hypothetical individuals with diﬀ erent health states and speciﬁ ed 
which person they deemed healthier than the other. These surveys covered 183 health states pertinent to GBD 2013; 
of these states, 30 were presented with descriptions revised from previous versions and 18 were new to GBD 2013. We 
analysed paired comparison data using probit regression analysis and rescaled results to disability weight units 
between 0 (no loss of health) and 1 (loss equivalent to death). We compared results with previous estimates, and an 
additional analysis examined sensitivity of paired comparison responses to duration of hypothetical health states.
Findings The total analysis sample consisted of 30 230 respondents from the GBD 2010 surveys and 30 660 from the 
new European surveys. For health states common to GBD 2010 and GBD 2013, results were highly correlated overall 
(Pearson’s r 0·992 [95% uncertainty interval 0·989–0·994]). For health state descriptions that were revised for this 
study, resulting disability weights were substantially diﬀ erent for a subset of these weights, including those related 
to hearing loss (eg, complete hearing loss: GBD 2010 0·033 [0·020–0·052]; GBD 2013 0·215 [0·144–0·307]) and 
treated spinal cord lesions (below the neck: GBD 2010 0·047 [0·028–0·072]; GBD 2013 0·296 [0·198–0·414]; neck 
level: GBD 2010 0·369 [0·243–0·513]; GBD 2013 0·589 [0·415–0·748]). Survey responses to paired comparison 
questions were insensitive to whether the comparisons were framed in terms of temporary or chronic outcomes 
(Pearson’s r 0·981 [0·973–0·987]). 
Interpretation This study substantially expands the empirical basis for assessment of non-fatal outcomes in the 
GBD study. Findings from this study substantiate the notion that disability weights are sensitive to particular details 
in descriptions of health states, but robust to duration of outcomes.
Funding European Centre for Disease Prevention and Control, Bill and Melinda Gates Foundation.
Copyright © Salomon et al. Open Access article distributed under the terms of CC BY-NC-ND. 
Introduction
The Global Burden of Disease (GBD) study is a 
systematic scientiﬁ c eﬀ ort to compare the magnitude of 
health losses associated with diﬀ erent diseases, injuries, 
and risk factors worldwide. Health losses are quantiﬁ ed 
in the GBD study with disability-adjusted life-years, a 
summary measure of population health that combines 
information about premature mortality, expressed 
as years of life lost, with information about non-fatal 
health losses attributable to time lived in states worse 
than full health, expressed as years lived with disability. 
To compute years lived with disability for a particular 
health outcome in a given population, the number of 
people living with that outcome is multiplied by a 
disability weight that represents the magnitude of 
health loss associated with the outcome. Disability 
weights are measured on a scale from 0 to 1, with 0 
implying a state that is equivalent to full health and 1 a 
state equivalent to death.
The conceptual and methodological basis for 
estimation of disability weights in the GBD study has 
changed with various iterations of the study,1–4 and 
some key issues relating to disability weights have been 
widely debated in the scientiﬁ c literature.5–19 For the 
GBD 2010 study,20–21 a new approach to computation of 
disability weights was developed, with an emphasis on 
eliciting of weights that were consistent with the 
GBD measurement construct of health loss as opposed 
to the broad construct of welfare loss. To this end, in 
the GBD 2010 disability weights measurement study,21 
we developed a new set of standardised methods for 
primary data collection from general public survey 
respondents in a diverse array of settings, and an 
associated set of data analytic approaches to enable 
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translation of these survey data into disability weights 
for all non-fatal outcomes included in the GBD.21
Data were collected in the GBD 2010 disability weights 
measurement study through a household survey in ﬁ ve 
countries and an open access web-based survey. The 
primary instrument for data collection was a simple 
paired comparison question in which respondents were 
asked to consider two hypothetical individuals, each with 
a particular health condition described brieﬂ y in terms of 
its main functional eﬀ ects and symptoms, and to state 
which of the two individuals they would deem as being 
healthier than the other. An additional type of question, 
included on the web-based survey only, asked respondents 
to compare the population health beneﬁ ts in two diﬀ erent 
hypothetical health programmes, and this information 
was used to anchor the results from the paired com-
parison data such that all weights were located on a scale 
between 0 and 1. The study produced a set of new dis-
ability weights, including measures of uncertainty for the 
220 unique health states that collectively captured 
variation across the full set of 1160 sequelae arising from 
the 289 disabling disease and injury causes in GBD 2010. 
These disability weights were incorporated into estimates 
of years lived with disability, disability-adjusted life-years, 
and a related summary measure of average population 
health called healthy life expectancy.22–24
An important limitation acknowledged in the GBD 2010 
disability weights measurement study was the crucial 
dependence of the results on the ways that outcomes 
were described to survey respondents.21 Presentation of 
health states in terms of brief lay descriptions necessitated 
a focus on the most salient and typical eﬀ ects on someone 
living in a particular health state. With the aim to balance 
validity and parsimony, descriptions invariably omitted 
some aspects of health states. Moreover, lay descriptions 
were developed collaboratively with individual expert 
groups—each organised around a particular set of health 
issues—and although eﬀ orts were made to ensure 
consistency across the set of conditions, some variability 
in language and detail remained. Commentators on the 
GBD 2010 disability weights measurement study have 
queried some of the results and suggested some speciﬁ c 
examples of aspects of the lay descriptions that could 
have introduced imbalance across diﬀ erent conditions 
or inconsistency across severity levels for a given 
condition.25–27
In GBD 2013,28 an expanded list of 306 disease and 
injury causes gives rise to 2337 sequelae, which have 
been mapped to 235 unique health states. In this study, 
we describe estimation of an updated set of disability 
weights for GBD 2013 via new data collection in four 
European countries and a reanalysis of existing and new 
data combined. In addition to updating the weights used 
for health states in GBD 2010 on the basis of an expanded 
set of survey data, the present study had three further 
objectives. The ﬁ rst objective was to estimate disability 
weights for additional sequelae that have been incor-
porated into GBD 2013 but were not included in 
GBD 2010. The second objective was to estimate revised 
disability weights for speciﬁ c sequelae for which GBD 2010 
lay descriptions lacked mention of an important 
symptom or consistency of wording across diﬀ erent 
levels of severity for the same impairment. The ﬁ nal 
objective was to assess one of the key assumptions in the 
Research in context
Evidence before this study
Before this study, the Global Burden of Disease (GBD) 2010 
disability weights measurement study constituted the largest 
empirical eﬀ ort to quantify health losses associated with a wide 
range of non-fatal eﬀ ects of disease and injury causes. The 2010 
disability weights measurement study introduced a new 
measurement approach relying on simple questions asked to 
respondents in the general community about which of two 
hypothetical people, each characterised by functional health 
levels and symptoms typical of a particular health condition, 
was regarded as being healthier than the other w as. Key 
methodological issues raised by that study were the design of 
the lay descriptions used to describe each pair of health 
outcomes to respondents and the extent to which the resulting 
weights were sensitive to the choice of respondent samples.
Added value of this study
This study adds to the existing scientiﬁ c literature for disability 
weights by doubling the empirical database for estimation of 
disability weights for the GBD study and exploring several key 
methodological issues at the frontier of the measurement 
agenda for disability weights. Speciﬁ cally, this study aimed to 
examine the robustness of disability weights estimates to 
variation in a range of diﬀ erent elements, including aspects of 
the descriptions that are used to present outcomes to survey 
respondents; the composition of survey respondents from 
diﬀ erent settings; and the framing of disability weights 
questions in terms of either temporary or chronic outcomes. 
Implications of all the available evidence
The new disability weights presented in this study provide 
quantitative estimates of health losses associated with 
non-fatal outcomes in GBD 2013. These weights answer 
questions about the comparative magnitude of health 
reductions due to a broad array of health outcomes and also 
supply an essential resource for clinicians and researchers 
investigating disease burden and policy makers who apply the 
results from these investigations. Findings from this study 
substantiate the plausibility of one important assumption in 
disability-adjusted life-years, which is that the comparative 
magnitude of health losses associated with diﬀ erent states 
might be stable over diﬀ erent durations of outcomes.
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GBD disability weight measurement approach, which is 
that comparative assessments of health states are 
insensitive to the duration of these outcomes.
Methods
Study design and participants
The dataset for analysis in this study combined data 
collected in the previous surveys21 done for the GBD 2010 
disability weights measurement study and a set of four 
new surveys done as part of the European disability 
weights measurement study.29 In the ﬁ rst component of 
GBD 2010, face-to-face household surveys were done in 
Bangladesh, Indonesia, Peru, and Tanzania in 2009–10 in 
samples designed to be representative of a speciﬁ c 
geographical area in each country, and a computer-assisted 
telephone survey was done in the USA, designed to be 
nationally representative. Sampling in the surveys used a 
multistage, stratiﬁ ed design, with probabilities of being 
selected proportional to population size. In the second 
component of GBD 2010, we ran a web-based survey, with 
recruitment of respondents through various channels, 
including news items and commentaries in journals, 
announcements at scientiﬁ c meetings, postings on 
relevant websites, online media campaigns, and direct 
outreach to members of the professional networks of the 
study investigators. In both the household and web-based 
surveys, eligible participants were aged 18 years or older.
For the present study, we collected new data in surveys 
that ran between Sept 23, 2013, and Nov 11, 2013, in 
Hungary, Italy, the Netherlands, and Sweden. The surveys 
were initiated in connection with a project sponsored by 
the European Centre for Disease Prevention and Control 
(the Burden of Communicable Diseases in Europe 
project),30 and the four countries were selected as 
representing four regions of Europe (east, south, middle, 
and north) with respect to age, sex, and education. 
Samples were drawn from existing internet panels in 
each country, which are standing panels of respondents 
who take part in surveys administered via the internet. 
We recruited respondents from each panel on the basis of 
quota sampling with reference to age, sex, and education 
(categorised by level of schooling completed) to maintain 
population representativeness with respect to these 
individual characteristics. In the Netherlands, we pre-
selected respondents before inviting them to partic ipate, 
which was possible because age, sex, and educational 
level were already known for the panel members; in the 
other three countries, we invited pane lists to participate 
via a website link and then selected them on the basis of 
their individual characteristics. All eligible participants 
were aged 18–65 years.
Procedures
We designed the European disability weights measure-
ment study29 to follow the protocol that was developed 
and applied in the GBD 2010 disability weights 
measurement study.21 Speciﬁ cally, the surveys relied 
mainly on a paired comparison task that asked 
respondents to consider descriptions of two hypothetical 
people, each with a particular health state, and specify 
which person they regarded as being healthier than the 
other. We presented health states with brief lay 
descriptions that focused on the major functional eﬀ ects 
and symptoms associated with each health state (the 
appendix has a complete listing of all lay descriptions 
used in this study). As a secondary measurement task, 
some versions of the survey included a population health 
equivalence question, which asked respondents to 
compare the health beneﬁ ts of diﬀ erent life-saving or 
health-improving programmes.
The European disability weights measurement study 
covered 255 health states, of which 183 have been used in 
GBD 2013. These 183 consisted of 135 of the 220 health 
states in GBD 2010 that were included in the European 
disability weights measurement study with unmodiﬁ ed 
lay descriptions; 30 from GBD 2010 for which alternative 
lay descriptions were included in the European disability 
weights measurement study; and 18 new ones that were 
added to GBD 2013 but not included in GBD 2010. The 
18 new states include ﬁ ve mild health states for alcohol 
and drug dependence outcomes; two for epilepsy, 
aligning with the epidemiological data that deﬁ ne severe 
epilepsy in people who have, on average, one or more ﬁ ts 
per month, and less severe epilepsy in those with 
between one and 11 ﬁ ts in the past year; two mild health 
states for low back pain; two for treated or untreated 
amputation of one arm; and one state each for stress 
incontinence, concussion, hypothyroidism, hyper-
thyroidism, thrombocytopenic purpura, vertigo, and 
borderline intellectual functioning. We developed the lay 
descriptions for these new states using the same design 
principles used in GBD 2010, with a focus on description 
of the most salient attributes of a health state 
parsimoniously using simple, non-clinical vocabulary.
For the 30 GBD 2010 health states that were included 
with modiﬁ ed lay descriptions in the European disability 
weights measurement study, with resulting weights used 
in GBD 2013, we developed the modiﬁ ed descriptions 
in response to identiﬁ ed issues in consistency of 
presentation across diﬀ erent related states (for four levels 
of intellectual disability and seven states relating to 
amputation) or identiﬁ ed instances in which the original 
descriptions omitted key components of the functional 
characterisation of the outcome. These omissions led to 
development of alternative descriptions that added 
reference to incontinence for four spinal cord lesion 
health states; added psychological eﬀ ects of social 
isolation for the three most severe hearing loss health 
states, and another three for those severities with 
inclusion of ringing in the ears, with revisions to the 
remaining hearing loss states to preserve consistency in 
presentation and ordering of these states; and 
incorporated minor revisions of the lay descriptions for 
mild depression, fracture of face bone, the three severity 
See Online for appendix
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levels for motor and cognitive impairment, and the 
generic health state for the worry associated with having 
a diagnosis of a chronic disease even if no symptoms are 
present. For these 30 states, the European disability 
weights measurement study included both the original 
and modiﬁ ed lay descriptions in the set of outcomes that 
were randomly allocated to respondents in pairs, with the 
restriction that no pairs would consist of both the original 
and modiﬁ ed description for the same state.
We randomly assigned (using a computer-generated 
random number sequence) respondents to one of three 
diﬀ erent versions of the web-based survey. One version 
(assigned to about 40% of respondents) included 
15 paired comparison questions (drawn randomly from 
all available possible comparisons) with a chronic 
framing. A second version (assigned to about 30% of 
respondents) included 15 paired comparison questions 
with a temporary framing. A third version (about 30% of 
respondents) included ﬁ ve paired questions with the 
same chronic framing used in the ﬁ rst version and three 
population health equivalence questions. In the chronic 
framing of paired comparison questions, respondents 
were asked to imagine that each of the health states 
in the pair would last for the rest of a person’s life. In 
the temporary framing of the paired comparison, respon-
dents were asked to imagine that each health state would 
last for 1 week. All survey versions included questions on 
basic sociodemographic attributes (age, sex, educational 
level, income, and diseases that they have had). In 
randomly selected subsamples of respondents, the same 
pair of health states was presented in the ﬁ rst and 15th 
paired comparison questions to allow assessment of 
test–retest reliability.
Survey questionnaires were translated from English 
into Dutch, Hungarian, Italian, and Swedish by native 
speakers with a medical background, and subsequently 
translated back into English. The translations were 
veriﬁ ed independently by bilingual native speakers.
We report on estimated disability weights for the set of 
235 states included in GBD 2013, consisting of the 
following categories: 135 states that were included in 
both GBD 2010 and the European disability weights 
measurement studies, with identical lay descriptions in 
both surveys; 50 states that are in GBD 2013 and were 
included in the GBD 2010 surveys and not in the 
European disability weights measurement study, but for 
which updated estimates emerge from the new analysis 
of pooled data; 30 states that were outcomes in both the 
GBD 2010 and 2013 studies, but for which GBD 2013 
estimates are based on revised lay descriptions included 
in the European disability weights measurement study; 
20 states that are new to GBD 2013, including 18 for 
which the new European disability weights measurement 
study provide data, and an additional two states for which 
the GBD 2010 surveys provide data. These last two states 
are monocular distance vision loss and headaches from 
drug use, which were included in the GBD 2010 surveys 
(and not the European disability weights measurement 
study), but not included as sequelae in the GBD 2010 
burden of disease calculations. 
Statistical analysis
We did all analyses in Stata/MP (version 11) and used the 
same analytic procedures applied in the GBD 2010 
disability weights measurement study.21 First, we pooled 
data for paired comparison responses from the original 
GBD 2010 dataset and the new European disability 
weights measurement study dataset. We ran probit 
regression analyses on the choice responses in the pooled 
data, with indicator variables for each health state that 
took the value 1 for the ﬁ rst state in a paired comparison, 
–1 for the second state in a paired comparison, and 0 for 
all states other than the pair being considered. The basic 
intuition of this modelling approach is that, in compar-
isons between states that produce similar losses of health, 
respondents are likely to disagree on which is healthier; in 
comparisons between states that produce very diﬀ erent 
health losses, respondents are more likely to agree on the 
ordering. The modelling strategy formalises this intuition 
into a statistical framework to infer the distances between 
values attached to diﬀ erent states on the basis of the 
observed frequencies of responses to paired comparison 
questions. With the probit regression, a second analytic 
step is needed to anchor the resulting estimates onto the 
0–1 disability weights scale. In view of a separate analysis29 
that suggested that the population health equivalence 
questions did not produce valid responses in the European 
disability weights measurement study, we anchored 
results from the probit regression analysis onto the 0–1 
scale using population health equivalence data from the 
GBD 2010 surveys and the same rescaling approach used 
in that study.21 The approach relied on a linear regression 
of the probit coeﬃ  cients from analysis of paired com-
parisons in the pooled dataset on the logit-transformed 
disability weight estimates derived from interval 
regression of the population health equivalence responses. 
We then estimated mean values for disability weights on 
the natural 0–1 scale using numerical integration. 
Analyses included a bootstrapping approach with 
1000 replicate samples to estimate uncertainty about 
mean values.
In addition to the main analysis used to establish 
disability weights for GBD 2013, we ran a secondary 
analysis to examine one of the key design features of the 
study, which is the way that chronic and temporary 
outcomes were assessed to develop comparable weights 
for all sequelae in the study. In the design, to avoid 
conﬂ ation of severity with duration, all paired comparison 
questions in a given survey version were standardised for 
duration of health states—ie, they asked people to 
compare two outcomes that both lasted an entire lifetime 
or 1 week, depending on whether respondents were 
randomly allocated to the chronic or temporary version. 
However, because overlap existed, by design, between 
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subsets of health states that were included in the two 
versions of the survey, we analysed all paired comparison 
responses together, with the overlapping states bridging 
the two sets to enable this simultaneous analysis and 
estimation of weights on a single scale. Implicitly, this 
approach assumes that paired comparison responses will 
be indiﬀ erent to whether outcomes are chronic or 
temporary. To test this assumption, we ran separate 
analyses on the chronic and temporary responses and 
compared the resulting coeﬃ  cients.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication. 
Results
Table 1 shows the characteristics of the study population, 
combining the sample used in the GBD 2010 disability 
weights measurement study with that in the European 
disability weights measurement study. Overall, the 
combined sample consists of 30 230 respondents from 
the GBD 2010 surveys and 30 660 from the European 
disability weights measurement study. As expected, the 
new sample is characterised by high levels of educational 
attainment typical of European populations and similar 
to the distribution of educational levels in the USA-
representative telephone survey. The European disability 
weights measurement study, by the design of the quota 
sampling scheme, shows an even balance by sex and a 
concentration of respondents in the age groups between 
30 years and 65 years (summarised in table 1 in the 
categories 30–49 years and 50–69 years, but with no 
respondents aged 66–69 years, by design of the study). 
Examining test–retest reliability across both the GBD and 
European disability weights measurement studies, we 
noted that of 7810 participants who responded to the 
same pair of states in the ﬁ rst and 15th paired comparison 
questions, 5574 (71%) of these responses were consistent. 
Overall consistency was examined with heat maps of 
response probabilities, both for the original GBD surveys21 
and the European disability weights measurement 
study,29 which substantiated a high degree of internal 
consistency in the aggregate response patterns to paired 
comparison questions.
Table 2 presents the estimated disability weights and 
95% uncertainty intervals for all 235 states in GBD 2013. 
Across all states, estimated weights ranged from 0·003 
(95% uncertainty interval 0·001–0·007) for mild distance 
vision impairment to 0·778 (0·606–0·900) for acute 
schizophrenia. The median weight across all states was 
0·128 (IQR 0·040–0·291), with 59 (25%) of the states 
having disability weights of less than 0·04.
For the purposes of description of results here, we 
report separately on disability weights for several 
diﬀ erent categories of states, distinguished by whether 
the states appeared in the GBD 2010 survey, European 
disability weights measurement study, or both, and 
whether the GBD 2013 weights are based on original 
(GBD 2010) or modiﬁ ed lay descriptions. The 
235 health states used in GBD 2013 include 185 that 
were also used in GBD 2010 (of 220 GBD 2010 states in 
total). Although only a subset of 135 of these states 
were included in the European disability weights 
measure ment study, all disability weights have been re-
estimated for the GBD 2013 on the basis of the full 
pooled dataset. For the subset of 135 included in both 
surveys, the revised weights for GBD 2013 take direct 
account of the additional paired comparison responses 
elicited in the new European disability weights 
measurement study; for the remaining 50, the 
estimated weights for GBD 2013 are aﬀ ected indirectly 
by the new data because all weights are estimated 
simultaneously on the basis of the full information 
contained in the pooled dataset, comprising interlocked 
paired comparison responses across all categories of 
states.
The appendix (p 12–17) presents the disability weights in 
GBD 2013 alongside the GBD 2010 weights for the 
185 states common to both studies. Comparing the 
two sets of weights (ﬁ gure 1), we ﬁ nd a high degree 
of correlation overall (Pearson’s r 0·992 [95% uncertainty 
interval 0·989–0·994]). For 36 (19%) states, the absolute 
value of the diﬀ erence between the previous and new 
weights was less than 0·002; for 105 (57%) states, the 
absolute value of the diﬀ erence was less than 0·01; 
the largest absolute value of the diﬀ erence was 0·13 for 
Household 
surveys 
(n=10 579)
USA surveys 
(n=3323)
GBD 2010 
web-based 
surveys 
(n=16 328)
European 
surveys 
(n=30 660)
Age (years)
18–29 3416 (32%) 181 (5%) 5186 (32%) 6338 (21%)
30–49 4799 (45%) 870 (26%) 6660 (41%) 13 989 (46%)
50–69 2003 (19%) 1412 (42%) 4127 (25%) 10 333 (34%)
≥70 361 (3%) 852 (26%) 355 (2%) 0
Unknown 0 8 (<1%) 0 0
Sex
Men 5814 (55%) 1230 (37%) 5268 (32%) 14 719 (48%)
Women 4765 (45%) 2092 (63%) 11 011 (67%) 15 941 (52%)
Unknown 0 11 (<1%) 49 (<1%) 0
Education
None 2234 (21%) 8 (<1%) 59 (<1%) 144 (<1%)
Primary 2785 (26%) 75 (2%) 11 (<1%) 834 (3%)
Secondary 3362 (32%) 1162 (35%) 1035 (6%) 11 335 (37%)
Higher 2198 (21%) 2063 (62%) 15 173 (93%) 18 347 (60%)
Unknown 0 15 (<1%) 50 (<1%) 0
Data are n (%). GBD=Global Burden of Disease.
Table 1: Characteristics of the study population 
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Estimate
Infectious disease
Infectious disease
Acute episode, mild 0·006 (0·002–0·012)
Acute episode, moderate 0·051 (0·032–0·074)
Acute episode, severe 0·133 (0·088–0·190)
Post-acute eﬀ ects (fatigue, emotional 
lability, and insomnia)
0·219 (0·148–0·308)
Diarrhoea
Mild 0·074 (0·049–0·104)
Moderate 0·188 (0·125–0·264)
Severe 0·247 (0·164–0·348)
Epididymo-orchitis 0·128 (0·086–0·180)
Herpes zoster 0·058 (0·035–0·090)
HIV: symptomatic, pre-AIDS 0·274 (0·184–0·377)
HIV/AIDS: receiving antiretroviral treatment 0·078 (0·052–0·111)
AIDS: not receiving antiretroviral treatment 0·582 (0·406–0·743)
Intestinal nematode infections: symptomatic 0·027 (0·015–0·043)
Lymphatic ﬁ lariasis: symptomatic 0·109 (0·073–0·154)
Ear pain 0·013 (0·007–0·024)
Tuberculosis
Without HIV infection 0·333 (0·224–0·454)
With HIV infection 0·408 (0·274–0·549)
Cancer
Cancer
Diagnosis and primary treatment 0·288 (0·193–0·399)
Metastatic 0·451 (0·307–0·600)
Mastectomy 0·036 (0·020–0·057)
Stoma 0·095 (0·063–0·131)
Terminal phase
With medication (for cancers and end-stage 
kidney or liver disease)
0·540 (0·377–0·687)
Without medication (for cancers and 
end-stage kidney or liver disease)
0·569 (0·389–0·727)
Cardiovascular and circulatory disease
Acute myocardial infarction
Days 1–2 0·432 (0·288–0·579)
Days 3–28 0·074 (0·049–0·105)
Angina pectoris
Mild 0·033 (0·020–0·052)
Moderate 0·080 (0·052–0·113)
Severe 0·167 (0·110–0·240)
Cardiac conduction disorders and cardiac 
dysrhythmias
0·224 (0·151–0·312)
Claudication 0·014 (0·007–0·025)
Heart failure
Mild 0·041 (0·026–0·062)
Moderate 0·072 (0·047–0·103)
Severe 0·179 (0·122–0·251)
Stroke
Long-term consequences, mild 0·019 (0·010–0·032)
Long-term consequences, moderate 0·070 (0·046–0·099)
Long-term consequences, moderate, plus 
cognition problems
0·316 (0·206–0·437)
(Table 2 continues in next column)
Estimate
(Continued from previous column)
Long-term consequences severe 0·552 (0·377–0·707)
Long-term consequences, severe, plus 
cognition problems
0·588 (0·411–0·744)
Diabetes and digestive and genitourinary disease
Diabetic foot 0·020 (0·010–0·034)
Diabetic neuropathy 0·133 (0·089–0·187)
Chronic kidney disease (stage 4) 0·104 (0·070–0·147)
End-stage renal disease
With kidney transplantation 0·024 (0·014–0·039)
On dialysis 0·571 (0·398–0·725)
Decompensated liver cirrhosis 0·178 (0·123–0·250)
Gastric bleeding 0·325 (0·209–0·462)
Crohn’s disease or ulcerative colitis 0·231 (0·156–0·320)
Benign prostatic hypertrophy: symptomatic 0·067 (0·043–0·097)
Urinary incontinence 0·139 (0·094–0·198)
Stress incontinence 0·020 (0·011–0·035)
Impotence 0·017 (0·009–0·030)
Infertility
Primary 0·008 (0·003–0·015)
Secondary 0·005 (0·002–0·011)
Chronic respiratory disease
Asthma
Controlled 0·015 (0·007–0·026)
Partly controlled 0·036 (0·022–0·055)
Uncontrolled 0·133 (0·086–0·192)
Chronic obstructive pulmonary disease and 
other chronic respiratory diseases
Mild 0·019 (0·011–0·033)
Moderate 0·225 (0·153–0·310)
Severe 0·408 (0·273–0·556)
Neurological disorders
Dementia
Mild 0·069 (0·046–0·099)
Moderate 0·377 (0·252–0·508)
Severe 0·449 (0·304–0·595)
Headache
Migraine 0·441 (0·294–0·588)
Tension-type 0·037 (0·022–0·057)
Medication overuse 0·223 (0·146–0·313)
Multiple sclerosis
Mild 0·183 (0·124–0·253)
Moderate 0·463 (0·313–0·613)
Severe 0·719 (0·534–0·858)
Epilepsy
Severe (seizures once per month or more) 0·552 (0·375–0·710)
Less severe (seizures less than once per 
month)
0·263 (0·173–0·367)
Parkinson’s disease
Mild 0·010 (0·005–0·019)
Moderate 0·267 (0·181–0·372)
Severe 0·575 (0·396–0·730)
(Table 2 continues in next column)
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Estimate
(Continued from previous column)
Mental, behavioural, and substance use disorders
Alcohol use disorder
Very mild 0·123 (0·082–0·177)
Mild 0·235 (0·160–0·327)
Moderate 0·373 (0·248–0·508)
Severe 0·570 (0·396–0·732)
Fetal alcohol syndrome
Mild 0·016 (0·008–0·030)
Moderate 0·056 (0·035–0·083)
Severe 0·179 (0·119–0·257)
Cannabis dependence
Mild 0·039 (0·024–0·060)
Moderate to severe 0·266 (0·178–0·364)
Amphetamine dependence
Mild 0·079 (0·051–0·114)
Moderate to severe 0·486 (0·329–0·637)
Cocaine dependence
Mild 0·116 (0·074–0·165)
Moderate to severe 0·479 (0·324–0·634)
Heroin and other opioid dependence
Mild 0·335 (0·221–0·473)
Moderate to severe 0·697 (0·510–0·843)
Anxiety disorders
Mild 0·030 (0·018–0·046)
Moderate 0·133 (0·091–0·186)
Severe 0·523 (0·362–0·677)
Major depressive disorder
Mild episode 0·145 (0·099–0·209)
Moderate episode 0·396 (0·267–0·531)
Severe episode 0·658 (0·477–0·807)
Bipolar disorder
Manic episode 0·492 (0·341–0·646)
Residual state 0·032 (0·018–0·051)
Schizophrenia
Acute state 0·778 (0·606–0·900)
Residual state 0·588 (0·411–0·754)
Anorexia nervosa 0·224 (0·150–0·312)
Bulimia nervosa 0·223 (0·149–0·311)
Attention-deﬁ cit hyperactivity disorder 0·045 (0·028–0·066)
Conduct disorder 0·241 (0·159–0·341)
Asperger’s syndrome 0·104 (0·071–0·147)
Autism 0·262 (0·176–0·365)
Borderline intellectual functioning 0·011 (0·005–0·020)
Intellectual disability
Mild 0·043 (0·026–0·064)
Moderate 0·100 (0·066–0·142)
Severe 0·160 (0·107–0·226)
Profound 0·200 (0·133–0·283)
Hearing and vision loss
Hearing loss
Mild 0·010 (0·004–0·019)
(Table 2 continues in next column)
Estimate
(Continued from previous column)
Moderate 0·027 (0·015–0·042)
Severe 0·158 (0·105–0·227)
Profound 0·204 (0·134–0·288)
Complete 0·215 (0·144–0·307)
Mild, with ringing 0·021 (0·012–0·036)
Moderate, with ringing 0·074 (0·049–0·107)
Severe, with ringing 0·261 (0·175–0·360)
Profound, with ringing 0·277 (0·182–0·387)
Complete, with ringing 0·316 (0·212–0·435)
Distance vision
Mild impairment 0·003 (0·001–0·007)
Moderate impairment 0·031 (0·019–0·049)
Severe impairment 0·184 (0·125–0·258)
Blindness 0·187 (0·124–0·260)
Monocular impairment 0·017 (0·009–0·029) 
Presbyopia 0·011 (0·005–0·020)
Musculoskeletal disorders
Low back pain
Mild 0·020 (0·011–0·035)
Moderate 0·054 (0·035–0·079)
Severe, without leg pain 0·272 (0·182–0·373)
Severe, with leg pain 0·325 (0·219–0·446)
Most severe, without leg pain 0·372 (0·250–0·506)
Most severe, with leg pain 0·384 (0·256–0·518)
Neck pain
Mild 0·053 (0·034–0·078)
Moderate 0·114 (0·075–0·162)
Severe 0·229 (0·153–0·317)
Most severe 0·304 (0·202–0·415)
Musculoskeletal problems
Legs, mild 0·023 (0·013–0·037)
Legs, moderate 0·079 (0·054–0·110)
Legs, severe 0·165 (0·112–0·232)
Arms, mild 0·028 (0·017–0·045)
Arms, moderate 0·117 (0·080–0·163)
Generalised, moderate 0·317 (0·216–0·440)
Generalised, severe 0·581 (0·403–0·739)
Gout: acute 0·295 (0·196–0·409)
Injury
Amputation
Finger(s), excluding thumb 0·005 (0·002–0·010)
Thumb: long term 0·011 (0·005–0·021)
One arm: long term, with treatment 0·039 (0·024–0·059)
One arm: long term, without treatment 0·118 (0·079–0·167)
Both arms: long term, with treatment 0·123 (0·081–0·176)
Both arms: long term, without treatment 0·383 (0·251–0·525)
Toe 0·006 (0·002–0·012)
One leg: long term, with treatment 0·039 (0·023–0·059)
One leg: long term, without treatment 0·173 (0·118–0·240)
Both legs: long term, with treatment 0·088 (0·057–0·124)
(Table 2 continues in next column)
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Estimate
(Continued from previous column)
Radius or ulna: long term, without treatment 0·043 (0·028–0·064)
Skull: short or long term, with or without 
treatment
0·071 (0·048–0·100)
Sternum or one or two ribs: short term, with 
or without treatment
0·103 (0·068–0·145)
Vertebral column: short or long term, with or 
without treatment
0·111 (0·075–0·156)
Treated, long term 0·005 (0·002–0·010)
Injured nerves
Short term 0·100 (0·067–0·140)
Long term 0·113 (0·076–0·157)
Injury to eyes: short term 0·054 (0·035–0·081)
Concussion 0·110 (0·074–0·158)
Traumatic brain injury
Severe: short term, with or without 
treatment
0·214 (0·141–0·297)
Long-term consequences, minor, with or 
without treatment
0·094 (0·063–0·133)
Long-term consequences, moderate, with or 
without treatment
0·231 (0·156–0·324)
Long-term consequences, severe, with or 
without treatment
0·637 (0·462–0·789)
Open wound: short term, with or without 
treatment
0·006 (0·002–0·012)
Poisoning: short term, with or without 
treatment
0·163 (0·109–0·227)
Severe chest injury
Long term, with or without treatment 0·047 (0·030–0·070)
Short term, with or without treatment 0·369 (0·248–0·501)
Spinal cord lesion
Below neck: treated 0·296 (0·198–0·414)
Below neck: untreated 0·623 (0·434–0·777)
At neck: treated 0·589 (0·415–0·748)
At neck: untreated 0·732 (0·544–0·871)
Other
Abdominopelvic problem
Mild 0·011 (0·005–0·021)
Moderate 0·114 (0·078–0·159)
Severe 0·324 (0·220–0·442)
Anaemia
Mild 0·004 (0·001–0·008)
Moderate 0·052 (0·034–0·076)
Severe 0·149 (0·101–0·209)
Periodontitis 0·007 (0·003–0·014)
Dental caries: symptomatic 0·010 (0·005–0·019)
Severe tooth loss 0·067 (0·045–0·095)
Disﬁ gurement
Level 1 0·011 (0·005–0·021)
Level 2 0·067 (0·044–0·096)
Level 3 0·405 (0·275–0·546)
Level 1, with itch or pain 0·027 (0·015–0·042)
Level 2, with itch or pain 0·188 (0·125–0·267)
Level 3, with itch or pain 0·576 (0·401–0·731)
(Table 2 continues in next column)
Estimate
(Continued from previous column)
Both legs: long term, without treatment 0·443 (0·297–0·589)
Burns
<20% of total surface area without lower 
airway burns: short term, with or without 
treatment
0·141 (0·094–0·196)
<20% of total surface area or <10% of total 
surface area if head or neck, or hands or wrist 
are involved: long term, with or without 
treatment
0·016 (0·008–0·028)
≥20% of total surface area: short term, with 
or without treatment
0·314 (0·211–0·441)
≥20% of total surface area or ≥10% of total 
surface area if head or neck, or hands or wrist 
are involved: long term, with treatment
0·135 (0·092–0·190)
≥20% of total surface area or ≥10% of total 
surface area if head or neck, or hands or wrist 
are involved: long term, without treatment
0·455 (0·302–0·601)
Lower airway: with or without treatment 0·376 (0·240–0·524)
Crush injury: short or long term, with or without 
treatment
0·132 (0·089–0·189)
Dislocation
Hip: long term, with or without treatment 0·016 (0·008–0·028)
Knee: long term, with or without treatment 0·113 (0·075–0·160)
Shoulder: long term, with or without 
treatment
0·062 (0·041–0·088)
Other injuries of muscles and tendons 
(consisting of sprains, strains, and dislocations 
other than shoulder, knee, or hip)
0·008 (0·003–0·015)
Drowning and non-fatal submersion: short or 
long term, with or without treatment
0·247 (0·164–0·341)
Fracture
Clavicle, scapula, or humerus: short or long 
term, with or without treatment
0·035 (0·021–0·053)
Face bone: short or long term, with or 
without treatment
0·067 (0·044–0·097)
Foot bones: short term, with or without 
treatment
0·026 (0·015–0·043)
Foot bones: long term, without treatment 0·026 (0·015–0·042)
Hand: short term, with or without treatment 0·010 (0·005–0·019)
Hand: long term, without treatment 0·014 (0·007–0·025)
Neck of femur: short term, with or without 
treatment
0·258 (0·172–0·356)
Neck of femur: long term, with treatment 0·058 (0·038–0·084)
Neck of femur: long term, without treatment 0·402 (0·269–0·541)
Other than neck of femur: short term, with or 
without treatment
0·111 (0·074–0·156)
Other than neck of femur: long term, 
without treatment
0·042 (0·027–0·063)
Patella, tibia or ﬁ bula, or ankle: short term, 
with or without treatment
0·050 (0·032–0·075)
Patella, tibia or ﬁ bula, or ankle: long term, 
with or without treatment
0·055 (0·036–0·081)
Pelvis: short term 0·279 (0·188–0·384)
Pelvis: long term 0·182 (0·123–0·253)
Radius or ulna: short term, with or without 
treatment
0·028 (0·016–0·046)
(Table 2 continues in next column)
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moderate-to-severe amphetamine dependence (for which 
the weight increased from 0·353 [95% uncertainty interval 
0·215–0·525] in GBD 2010 to 0·486 [0·329–0·637] in 
GBD 2013). Diﬀ erences were less than 5% for 68 (37%) 
states and less than 20% for 148 (80%) states; the largest 
relative diﬀ erence was 61% for short-term fracture of the 
hand (for which the weight decreased from 0·025 
[0·013–0·043] in GBD 2010 to 0·010 [0·005–0·019] in 
GBD 2013). Other states with large diﬀ erences included 
severe infectious disease episodes and post-infection 
symptoms; treated HIV/AIDS cases; cardiac conduction 
disorders; diabetic neuropathy; controlled asthma; various 
substance use disorders; some outcomes relating to 
burns; several injury-related states, including short-term 
fractures and eye injuries; and a generic state consisting 
of worry and daily drugs for an uncomplicated disease 
(appendix). Within the subset of 50 states that are common 
to GBD 2010 and 2013 but not included in the European 
disability weights measurement study (appendix p 16–17), 
diﬀ erences were substantially smaller than for those that 
were included in the European disability weights 
measurement study, as expected, with the maximum 
absolute diﬀ erence across states being 0·02 and the 
maximum relative diﬀ erence 18%.
For 30 states in GBD 2013, new descriptions were 
developed to replace those used in GBD 2010. The 
appendix (p 18–21) shows a comparison of weights for 
states that have had their lay descriptions revised for the 
2013 study. Minor changes in lay descriptions produced 
the expected minor shifts in disability weights for some 
outcomes, including mild depression, motor and 
cognitive impairments, and intellectual disabilities. 
Revisions to a series of states relating to amputations 
resulted in a mixture of small and moderate changes to 
the associated disability weights. The most sizeable 
changes to disability weights were in those relating to 
hearing loss, for which addition of the previously 
omitted references to diﬃ  culties with communication 
and relating to other people resulted in increases in the 
disability weights for the more severe levels of hearing 
loss, with complete hearing loss changing from 0·033 
(95% uncertainty interval 0·020–0·052) in the previously 
published GBD 2010 disability weights measurement 
study21 to 0·215 (0·144–0·307) in GBD 2013. Another set 
of outcomes with substantial changes to the weights 
resulting from revision of lay descriptions was the series 
of four states relating to spinal cord lesions; the largest 
of these changes pertained to the two treated states, with 
the weight for treated spinal cord lesions below the 
neck increasing from 0·047 (0·028–0·072) to 0·296 
(0·198–0·414), and for treated spinal cord lesions at neck 
level increasing from 0·369 (0·243–0·513) to 0·589 
(0·415–0·748).
For a ﬁ nal grouping of outcomes new to GBD 2013, the 
appendix (p 22) presents lay descriptions and estimated 
disability weights. Of these disability weights, the lowest 
were for borderline intellectual functioning, at 0·011 
(0·005–0·020), and distance vision, monocular im-
pairment, at 0·017 (0·009–0·029). The highest disability 
weights were for severe epilepsy, at 0·552 (0·375–0·710), 
and mild heroin and other opioid dependence, at 0·335 
(0·221–0·473).
To assess the implicit assumption that paired 
comparison responses are insensitive to whether 
outcomes are presented as either chronic or temporary 
(standardised for both outcomes within a pair, either as 
lifetime or 1 week duration, depending on the survey 
version), we ran separate probit analyses on paired 
comparison responses for states included in the survey 
version using a chronic formulation of the paired 
comparison (including 201 GBD 2013 states) and a 
temporary formulation (including 142 GBD 2013 
states). For the 108 GBD 2013 states appearing in both 
sets, the coeﬃ  cients from the separate probit reg-
ressions were highly correlated (Pearson’s r 0·981 
[95% uncertainty interval 0·973–0·987]). Figure 2 is a 
scatter plot of the results from the chronic and 
temporary regressions. The states with the largest 
deviations from the linear relation between the two sets 
of regression coeﬃ  cients included speech problems 
and rectovaginal ﬁ stulas, which had chronic values that 
were less severe than what would be predicted from the 
temporary values, and untreated HIV/AIDS cases, 
which had a chronic value that was more severe than 
that expected in relation to the temporary value. 
Estimate
(Continued from previous column)
Generic uncomplicated disease
Worry and daily medication 0·049 (0·031–0·072)
Anxiety about diagnosis 0·012 (0·006–0·023)
Iodine-deﬁ ciency goitre 0·199 (0·133–0·276)
Kwashiorkor 0·051 (0·031–0·079)
Severe wasting 0·128 (0·082–0·183)
Speech problems 0·051 (0·032–0·078)
Motor impairment
Mild 0·010 (0·005–0·019)
Moderate 0·061 (0·040–0·089)
Severe 0·402 (0·268–0·545)
Motor and cognitive impairments
Mild 0·031 (0·018–0·050)
Moderate 0·203 (0·134–0·290)
Severe 0·542 (0·374–0·702)
Rectovaginal ﬁ stula 0·501 (0·339–0·657)
Vesicovaginal ﬁ stula 0·342 (0·227–0·478)
Thrombocytopenic purpura 0·159 (0·106–0·226)
Hypothyroidism 0·019 (0·010–0·032)
Hyperthyroidism 0·145 (0·096–0·202)
Vertigo 0·113 (0·074–0·158)
Data in parentheses are 95% uncertainty intervals.
Table 2: Disability weights for 235 unique health states in the Global 
Burden of Disease 2013 study
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Discussion
In this study, we build on the previous disability weights 
measurement study for GBD 2010, with a substantial 
expansion of the empirical database of comparative 
assessments for a range of health outcomes. In the new 
analysis, with a combined sample that doubles the 
number of respondents from the original dataset, we 
note that most disability weights are minimally aﬀ ected 
by the change in composition of the sample towards one 
in which respondents from European countries now 
make up most survey participants. Several exceptions to 
this general ﬁ nding exist, however, including some states 
for which weights are substantially higher in the 
European disability weights measurement study than in 
GBD 2010 (eg, treated HIV/AIDS cases, cardiac con-
duction disorders, controlled asthma, short-term burn 
injuries, and a generic state for worry and daily drug use 
associated with an uncomplicated diagnosed disease), 
and some for which they are substantially lower in the 
new study than in the old study (eg, severe infections and 
short-term states relating to fractures of the hands, arms, 
or legs). Although this study was not designed to develop 
or test speciﬁ c hypotheses about why the introduction of 
a large European respondent sample might have pro-
duced results that diﬀ ered from existing estimates in 
these ways, such questions are worth further exploration, 
especially in cases for which these diﬀ erences could have 
substantial implications for the magnitude or ranking of 
particular disease burdens.
With incorporation of the new survey data from four 
European countries in estimation of disability weights 
for GBD 2013, the cumulative evidence base for 
measurement of these weights is now mostly made up of 
respondents from high-income settings. The previously 
noted ﬁ nding that paired comparison responses are 
largely consistent across very distinct settings21 and the 
ﬁ nding in this study that most disability weights did not 
change substantially in the new pooled analysis together 
oﬀ er some reassurance that most disease burden 
calculations will be reasonably robust to this shift. 
However, the exceptions noted above of some disability 
weights that did change substantially in the new analysis 
are important to acknowledge and their implications 
considered. Eﬀ orts to collect more data for disability 
weights in diﬀ erent settings are planned or underway. 
Work should continue on assessment of the sensitivity of 
key GBD ﬁ ndings to changes in the composition of 
respondents who inform estimation of disability weights 
for the worldwide analysis.
In addition to examination of the sensitivity of disability 
weights to the composition of sample respondents, this 
study also oﬀ ers evidence for the eﬀ ect of inclusion of 
speciﬁ c elements in or exclusion of the elements from 
lay descriptions of outcomes presented as stimuli for 
paired comparison questions. Our analysis has revealed 
several states for which the changes in lay descriptions 
from those used in GBD 2010 were associated with major 
revisions of the weights, notably the increase in weights 
for a range of hearing loss outcomes, especially at severe 
levels, when explicitly accounting for eﬀ ects of social 
isolation. These changes reinforce the inherent limitation 
in an approach based on use of brief lay descriptions in 
presentation of outcomes in paired comparisons, which 
is that, in some cases, responses are evidently highly 
sensitive to particular details in these descriptions. An 
Figure 2: Comparison of probit coeﬃ  cients estimated from responses to the version of the questionnaire 
with the chronic framing versus the version of the questionnaire with the temporary framing 
The three states showing the largest deviations from the linear relation between the two sets of regression 
coeﬃ  cients are labelled as follows: (A) speech problems; (B) AIDS cases not receiving antiretroviral treatment; 
(C) rectovaginal ﬁ stula.
Ch
ro
ni
c p
ai
re
d 
co
m
pa
ris
on
 re
sp
on
se
s
Temporary paired comparison responses
1·5
1·51·00·50–0·5–1·0
1·0
0·5
0
–0·5
–1·0
A
B
C
GB
D 
20
13
 d
isa
bi
lit
y 
w
ei
gh
t
0 0·2 0·4 0·6 0·8
0·8
0·6
0·4
0·2
0
GBD 2010 disability weight
Included in European disability weights measurement study
Not included in European disability weights measurement study
A B
C
Figure 1: Comparison of disability weights from GBD 2010 and 2013 for 135 states included and 50 not 
included in the European disability weights measurement study
The three states with the largest absolute diﬀ erences between the GBD 2010 and 2013 weights are labelled as 
follows: (A) amphetamine dependence: moderate to severe; (B) cocaine dependence: moderate to severe; 
(C) fracture of pelvis: short term. GBD=Global Burden of Disease. 
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example of a potential concern with some lay descriptions, 
which persists from the original GBD 2010 study, is the 
case of illicit drug use disorders, which have weights that 
are higher than those reported in other studies. We have 
hypothesised that part of the explanation for this result is 
that lay descriptions for illicit drug use disorders include 
explicit reference to drug use as the cause of the 
functional outcomes described, whereas we have de-
liberately avoided this sort of labelling in other health 
states. Further examination of the potential for bias 
relating to explicit labelling of causes such as drug use 
disorders remains a priority. Close inspection of these 
results, as with the original publication of the disability 
weights for GBD 2010, will undoubtedly lead to 
identiﬁ cation of other examples of weights that seem 
counterintuitive. These types of ﬁ ndings need to be 
addressed with empirical investigation to understand 
whether the weights in question are sensitive to speciﬁ c 
elements in the lay descriptions, or whether some other 
explanation might emerge.
A major methodological and empirical agenda remains 
to improve the basis of standardised description of 
outcomes, which depends on two key advances. First, 
methods are needed to parsimoniously present the major 
functional and symptom-related attributes for a highly 
diverse set of health outcomes captured in the GBD study, 
which has to balance the diversity of attributes with the 
cognitive demands of people comparing outcomes that 
diﬀ er in many dimensions. Second, these descriptions 
need to be driven by empirical data for the proﬁ les of 
individuals living with each outcome, drawn from 
representative samples of such individuals; these samples 
will, in many cases, be diﬃ  cult to identify or recruit, and 
this would represent a vast and ambitious new data 
collection enterprise.
One of the contributions of this study is new evidence 
for the robustness of paired comparison responses to 
framing of outcomes in the paired comparison as either 
chronic or temporary. We note that health state 
comparisons are largely insensitive to this framing 
choice. This ﬁ nding suggests that our approach of 
simultaneous estimation of cardinal severity values from 
a pooled dataset with a combination of responses to 
chronic and temporary paired comparisons is a 
reasonable methodological choice.
On the other hand, we reiterate some important 
limitations in the study that carry over from the previous 
disability weights measurement study for GBD 2010. 
Our approach to anchor disability weights on a 0–1 scale 
continues to depend on a small number of responses to 
a population health equivalence question that was 
included in the GBD 2010 web-based surveys. 
Elsewhere,29 we have noted that the discrete choice 
formulation of this question seems to be susceptible to a 
large amount of measurement error in a general 
population sample (as used in the European disability 
weights measurement study, by contrast with the self-
selected sample of respondents to the GBD 2010 web-
based survey), making this type of question format 
unsuitable for use as an anchoring device. Speciﬁ cally, 
we examined the European population health equiva-
lence responses for both sensitivity to scope and 
responsiveness to variation in severity of the diﬀ erent 
outcomes under consideration. In both cases, patterns 
of response were consistent with large proportions of 
respondents answering randomly, which compromised 
the goal of scaling disability weights on the basis of the 
results of these responses. Moving forward, new 
approaches might be needed to anchor estimates from 
paired comparisons onto the scale needed for disability 
weights. At present, limited evidence exists for how 
trade-oﬀ s between non-fatal outcomes and changes in 
mortality vary across settings, so resolution of this 
question continues to await further empirical exam-
ination. These questions, both methodological and 
empirical, remain important priorities for investigation 
within the continuing GBD research agenda.
As the GBD enterprise has committed to annual 
updates of the systematic reviews and pooling of available 
data for deaths, prevalence of disease, and the 
contribution of risk factors, aiming to take account of all 
the available evidence, in the same spirit, new 
information about disability weights will be reviewed and 
incorporated into GBD estimates as it becomes available. 
The high degree of consistency between the ﬁ ndings of 
the original GBD and the recent European disability 
weights measurement study lends further support to 
their pooled use to inform comparable burden of disease 
estimates for all countries. Evidently, more important 
than between-country variation are the substantial 
changes in estimated levels of disability weights that can 
result from addition of a new symptom or alteration of 
the wording of lay descriptions of a health state. As the 
GBD study expands, opportunities for new survey work 
will need to be seized to further explore some of these 
methodological issues and allow consistent valuation of 
health states characterising newly added diseases.
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